The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat ...

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first standalone therapy for adults suffering from major depressive disorder ...

PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe ...

The United States Food and Drug Administration (FDA) has approved Spravato (esketamine), a nasal spray from Johnson & Johnson, as a stand-alone therapy for adults with major depressive disorder ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Johnson & Johnson, said in a news release. “For too long, health care providers have had few options to offer patients much-needed symptom improvement." The nasal spray was first approved by the ...

The Food and Drug Administration on Tuesday approved Johnson & Johnson's nasal spray to be used alone in adults with a major ...

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral antidepressants, according to a news release issued by Johnson & Johnson.